Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update

Esperion Therapeutics, Inc. (NASDAQ:ESPR) saw a significant decrease in short interest in May. As of May 15th, there was short interest totaling 20,207,976 shares, a decrease of 44.5% from the April 30th total of 36,425,941 shares. Currently, 8.0% of the shares of the company are sold short. Based on an average trading volume of 31,841,027 shares, the short-interest ratio is currently 0.6 days.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR traded up $0.01 during trading hours on Tuesday, hitting $3.14. The company’s stock had a trading volume of 14,032,972 shares, compared to its average volume of 8,879,262. The stock has a market cap of $808.33 million, a price-to-earnings ratio of -52.33, a P/E/G ratio of 2.54 and a beta of 1.07. Esperion Therapeutics has a 12 month low of $0.91 and a 12 month high of $4.18. The business has a 50-day simple moving average of $2.63 and a 200-day simple moving average of $3.12.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.08). The business had revenue of $80.10 million during the quarter, compared to the consensus estimate of $84.52 million. Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%. On average, equities research analysts forecast that Esperion Therapeutics will post 0.05 EPS for the current year.

Institutional Trading of Esperion Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sivia Capital Partners LLC purchased a new position in shares of Esperion Therapeutics during the second quarter valued at approximately $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Esperion Therapeutics during the third quarter valued at approximately $29,000. R Squared Ltd bought a new stake in Esperion Therapeutics in the 3rd quarter worth approximately $33,000. Kestra Advisory Services LLC bought a new stake in Esperion Therapeutics in the 4th quarter worth approximately $35,000. Finally, KFG Wealth Management LLC bought a new stake in Esperion Therapeutics in the 4th quarter worth approximately $37,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ESPR. Needham & Company LLC lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. HC Wainwright downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 target price on the stock. in a research report on Friday, May 1st. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. Finally, Cantor Fitzgerald lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and an average price target of $5.54.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.